The great immune escape: understanding the divergent immune response in breast cancer subtypes

SS Onkar, NM Carleton, PC Lucas, TC Bruno… - Cancer …, 2023 - aacrjournals.org
Breast cancer, the most common type of cancer affecting women, encompasses a collection
of histologic (mainly ductal and lobular) and molecular subtypes exhibiting diverse clinical …

Breast cancer: current perspectives on the disease status

M Fahad Ullah - Breast cancer metastasis and drug resistance …, 2019 - Springer
Breast cancer is the most frequently diagnosed cancer in women and ranks second among
causes for cancer related death in women. Evidence in literature has shown that the past …

Cancer progress and priorities: breast cancer

SC Houghton, SE Hankinson - Cancer epidemiology, biomarkers & …, 2021 - aacrjournals.org
Breast cancer is the most commonly diagnosed invasive cancer among women both
globally and within the United States and the number one cause of cancer-related deaths …

Breast cancer: conventional diagnosis and treatment modalities and recent patents and technologies

MI Nounou, F ElAmrawy, N Ahmed… - Breast cancer: basic …, 2015 - journals.sagepub.com
Breast cancer is the most prevalent cancer among women worldwide. However, increased
survival is due to the dramatic advances in the screening methods, early diagnosis, and …

DRDA-Net: Dense residual dual-shuffle attention network for breast cancer classification using histopathological images

S Chattopadhyay, A Dey, PK Singh, R Sarkar - Computers in biology and …, 2022 - Elsevier
Breast cancer is caused by the uncontrolled growth and division of cells in the breast,
whereby a mass of tissue called a tumor is created. Early detection of breast cancer can …

The role of oxidative stress on breast cancer development and therapy

F Hecht, CF Pessoa, LB Gentile, D Rosenthal… - Tumor biology, 2016 - Springer
Reactive oxygen species (ROS) are produced by both enzymatic and non-enzymatic
systems within eukaryotic cells and play important roles in cellular physiology and …

Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: A systematic review and meta-analysis

Y Ergun, G Ucar, B Akagunduz - Cancer Treatment Reviews, 2023 - Elsevier
Background The prognostic differences between HER2-zero and HER2-low breast cancer
(BC) remain unclear. Purpose of this meta-analysis is to investigate the differences between …

Mitochondrial miRNAs (MitomiRs): their potential roles in breast and other cancers

E Erturk, OE Onur, O Akgun, G Tuna, Y Yildiz, F Ari - Mitochondrion, 2022 - Elsevier
Breast cancer is the most common cancer in women worldwide. MicroRNAs (miRNAs) are
non-coding RNAs that are involved in the post-transcriptional regulation of gene expression …

KDM5 family as therapeutic targets in breast cancer: Pathogenesis and therapeutic opportunities and challenges

CY Li, W Wang, CH Leung, GJ Yang, J Chen - Molecular cancer, 2024 - Springer
Breast cancer (BC) is the most frequent malignant cancer diagnosis and is a primary factor
for cancer deaths in women. The clinical subtypes of BC include estrogen receptor (ER) …

Treatment of estrogen receptor-positive breast cancer

F Lumachi, A Brunello, M Maruzzo… - Current medicinal …, 2013 - benthamdirect.com
Estrogen receptor (ER) expression is the main indicator of potential responses to endocrine
therapy (ET), and approximately 70% of human breast cancers (BCs) are hormone …